SCHEMBL17614549

SCHEMBL17614549

Cc1cccc(-n2nnn(C)c2=O)c1COc1cccc(-c2ccc(N(C)C)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.39
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
FFAR1 O14842 1/20 0.35
PPARD Q03181 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
PTGER4 P35408 1/20 0.34
BCL2 P10415 1/20 0.33
BAX Q07812 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
SOD1 P00441 1/20 0.33
DHODH Q02127 1/20 0.33
MRGPRX4 Q96LA9 2/20 0.32
SLC16A3 O15427 1/20 0.32
SLC16A1 P53985 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16206150 0.90 SLC22A12 (0.41) SLC22A12FFAR1NR1H4PTGER4RXRA
SCHEMBL16205967 0.90 SLC22A12 (0.42) SLC22A12FFAR1NR1H4PTGER4RXRA
SCHEMBL17614547 0.88 PTGER4 (0.40) SLC22A12FFAR1NR1H4PTGER4DHODH
SCHEMBL17614551 0.88 MRGPRX4 (0.43) SLC22A12FFAR1NR1H4PTGER4RXRA
SCHEMBL16206147 0.88 SLC22A12 (0.40) SLC22A12FFAR1NR1H4PTGER4RXRA
SCHEMBL17614546 0.87 SLC22A12 (0.39) SLC22A12FFAR1NR1H4PTGER4RXRA
SCHEMBL16206146 0.87 SLC22A12 (0.42) SLC22A12FFAR1PPARDNR1H4PTGER4
SCHEMBL17614548 0.87 SLC22A12 (0.42) SLC22A12FFAR1PTGER4
SCHEMBL17615154 0.86 SLC22A12 (0.39) SLC22A12FFAR1PPARDNR1H4PTGER4
SCHEMBL17615163 0.86 PPARD (0.40) SLC22A12PRMT5WDR77FFAR1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME MT-CO1, SOD1, MT-CO2 SLC22A12 3344/4885PRMT5 1347/4885WDR77 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.